Zoetis Inc. (NYSE:ZTS) Shares Sold by TCG Advisory Services LLC

TCG Advisory Services LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 5.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,339 shares of the company’s stock after selling 81 shares during the quarter. TCG Advisory Services LLC’s holdings in Zoetis were worth $264,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Stratos Wealth Advisors LLC acquired a new position in Zoetis during the third quarter worth $209,000. Independent Advisor Alliance lifted its position in Zoetis by 9.3% in the 3rd quarter. Independent Advisor Alliance now owns 2,509 shares of the company’s stock valued at $437,000 after acquiring an additional 213 shares in the last quarter. Everhart Financial Group Inc. grew its position in shares of Zoetis by 10.9% in the 3rd quarter. Everhart Financial Group Inc. now owns 1,407 shares of the company’s stock valued at $245,000 after acquiring an additional 138 shares during the period. Verdence Capital Advisors LLC lifted its position in Zoetis by 12.2% during the third quarter. Verdence Capital Advisors LLC now owns 2,791 shares of the company’s stock worth $486,000 after acquiring an additional 303 shares during the last quarter. Finally, Brighton Jones LLC grew its position in shares of Zoetis by 9.3% during the 3rd quarter. Brighton Jones LLC now owns 2,783 shares of the company’s stock worth $484,000 after purchasing an additional 237 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the transaction, the executive vice president now directly owns 20,417 shares in the company, valued at approximately $4,037,257.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 2,209 shares of company stock worth $371,293. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ZTS. Piper Sandler restated an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Barclays decreased their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Stifel Nicolaus reduced their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Finally, The Goldman Sachs Group lifted their price target on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $216.13.

Zoetis Stock Down 0.5 %

Shares of Zoetis stock traded down $0.88 during trading hours on Monday, reaching $166.19. The company’s stock had a trading volume of 557,151 shares, compared to its average volume of 3,147,119. The company has a market capitalization of $75.83 billion, a P/E ratio of 32.19, a P/E/G ratio of 2.62 and a beta of 0.86. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The stock’s fifty day simple moving average is $168.88 and its two-hundred day simple moving average is $178.93. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The company had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.31 EPS. On average, research analysts forecast that Zoetis Inc. will post 5.77 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is currently 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.